Trial Profile
Pivotal follow-on trial of TMX 101, an intravesicular formulation of imiquimod, in patients with carcinoma in situ bladder cancer
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 05 Dec 2013
Price :
$35
*
At a glance
- Drugs Imiquimod (Primary)
- Indications Bladder cancer
- Focus Registrational; Therapeutic Use
- Sponsors Telormedix
- 05 Dec 2013 New trial record
- 02 Dec 2013 Telormedix has raised Series B financing to support the phase II trial of TMX 101 and finance the planning of a follow on trial, according to a company media release.